“MEDI&GENE’s Solution,”

First-in-Class Therapeutics with Novel Target & Multiple Effects

History
  • 2025
    2025
    09. Headquarters expansion and relocation to Korea University TechnoComplex building
    04. Selected for the Super Gap Startup 1000+ Program (Ministry of SMEs and Startups)
  • 2024
    2024
    12. Selected for the Scale-up TIPS Program (Ministry of SMEs and Startups)
    06-10. Series A financing
  • 2023
    2023
    12. Executed a Material Transfer Agreement (MTA) with a global top-tier pharmaceutical company
    08. Headquarters relocation to Seoul BioHub
    07. Established a strategic partnership with a global top-tier pharmaceutical company
  • 2022
    2022
    08. Selected for the TIPS Startup Commercialization Support program (Ministry of SMEs and Startups)
    07-10. Pre-Series A financing
  • 2021
    2021
    11. Established the MEDI&GENE Corporate Bio Research Institute
    08. Selected for the TIPS program (Ministry of SMEs and Startups)
    07. Became a subsidiary of Korea University Holdings. Seed Round financing
    06. Incorporated MEDI&GENE Co., Ltd.